Latest News for: cd20

Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Form 6-K) (Legend Biotech Corporation)

Public Technologies 15 Jun 2026
LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion.
Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, ...

Killeen Daily Herald 14 Jun 2026
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory ....
Edit

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (Legend Biotech Corporation)

Public Technologies 14 Jun 2026
) Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ... The CD19/ CD20 ...
Edit

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

PR Newswire 08 Jun 2026
KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to achieve deep B-cell depletion ... KT209 is a novel CD19 x CD20 x CD3 trispecific ...
Edit

Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome (Chugai Pharmaceutical Co Ltd)

Public Technologies 14 May 2026
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome ... Gazyva is a glycoengineered type II anti-CD20 monoclonal antibody designed to bind ...
Edit

Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome (Nippon Shinyaku Co Ltd)

Public Technologies 14 May 2026
4519) announced today that Chugai filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for the anti-cancer agent/humanized anti-CD20 monoclonal antibody Gazyva® for Intravenous Infusion 1000 mg [generic name.
Edit

Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody) (Chugai Pharmaceutical Co Ltd)

Public Technologies 09 Apr 2026
). Zenyaku Kogyo Co., Ltd. Chugai Pharmaceutical Co., Ltd. Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody). TOKYO, April 9, 2026 -- Zenyaku Kogyo Co., Ltd ... (TOKYO ... Attachments Original document Permalink.
Edit

AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

PR Newswire 02 Apr 2026
AVC-203 is the world's first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing ... CD19/CD20 through bi- or tri-specific bridging proteins.
  • 1

Article Search

tools
×
×
×
×